Estudo randomizado | Alopurinol não melhora os desfechos em pacientes com doença cardíaca isquêmica sem gota prévia.

Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial – The Lancet

Comentário convidado: Xanthine oxidase inhibition for cardiovascular disease prevention – The Lancet

Conteúdo relacionado: [News release – not published yet] #ESCCongress – RCT | Allopurinol does not improve cardiovascular outcomes in ischemic heart disease patients.

Comentário no Twitter

Despite favorable effects on surrogate endpoints in smaller trials, in an RCT trial of 5,721 pts with CAD, allopurinol did not significantly improve cardiovascular prognosis compared to placebo https://t.co/ITW4HAwI2K @TheLancet pic.twitter.com/EggHM8flle

— Pradeep Natarajan (@pnatarajanmd) October 7, 2022

Sob licença de Creative Commons Attribution (CC BY 4.0)